These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18387935)

  • 41. Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.
    Pagotto U; Pasquali R
    Lancet; 2005 Apr 16-22; 365(9468):1363-4. PubMed ID: 15836868
    [No Abstract]   [Full Text] [Related]  

  • 42. Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome.
    Kapoor S
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):339. PubMed ID: 18625002
    [No Abstract]   [Full Text] [Related]  

  • 43. Recent advances in CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.
    Banasch M; Goetze O; Schmidt WE; Meier JJ
    Liver Int; 2007 Oct; 27(8):1152-5. PubMed ID: 17845546
    [No Abstract]   [Full Text] [Related]  

  • 45. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
    Steinberg BA; Cannon CP
    Am J Cardiol; 2007 Dec; 100(12A):27P-32P. PubMed ID: 18154743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of rimonabant on weight reduction and cardiovascular risk.
    van Oosten B; Killestein J; Polman Ch
    Lancet; 2005 Jul 30-Aug 5; 366(9483):368-9; author reply 369-70. PubMed ID: 16054933
    [No Abstract]   [Full Text] [Related]  

  • 47. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.
    Lafontan M; Piazza PV; Girard J
    Diabetes Metab; 2007 Apr; 33(2):85-95. PubMed ID: 17418607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
    Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A
    Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation].
    Kvasnicka T
    Cas Lek Cesk; 2005; 144(2):81-4; discussion 85. PubMed ID: 15807291
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
    Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].
    MMW Fortschr Med; 2007 Jun; 149(27-28):8. PubMed ID: 17717874
    [No Abstract]   [Full Text] [Related]  

  • 52. [Rimonabant. Risk of depression has not been finally clarified].
    Kreutzkamp B
    Med Monatsschr Pharm; 2008 May; 31(5):191-2. PubMed ID: 18552079
    [No Abstract]   [Full Text] [Related]  

  • 53. Rimonabant: obituary for a wonder drug.
    Boekholdt SM; Peters RJ
    Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
    [No Abstract]   [Full Text] [Related]  

  • 54. Effect of rimonabant on weight reduction and cardiovascular risk.
    Hirschel B
    Lancet; 2005 Jul 30-Aug 5; 366(9483):369; author reply 369-70. PubMed ID: 16054934
    [No Abstract]   [Full Text] [Related]  

  • 55. [Blocking cannabinoid receptors. Simultaneous control of overweight and nicotine addiction].
    MMW Fortschr Med; 2004 Mar; 146(10):44. PubMed ID: 15347084
    [No Abstract]   [Full Text] [Related]  

  • 56. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
    Janiak P; Poirier B; Bidouard JP; Cadrouvele C; Pierre F; Gouraud L; Barbosa I; Dedio J; Maffrand JP; Le Fur G; O'Connor S; Herbert JM
    Kidney Int; 2007 Dec; 72(11):1345-57. PubMed ID: 17882151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The safety of obesity drugs.
    Van Gaal LF; Scheen AJ; Formiguera X
    Expert Opin Drug Saf; 2007 Sep; 6(5):475-6; author reply 477-8. PubMed ID: 17877434
    [No Abstract]   [Full Text] [Related]  

  • 59. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.
    Aronne LJ; Isoldi KK
    Am J Cardiol; 2007 Dec; 100(12A):18P-26P. PubMed ID: 18154742
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
    Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.